JNJ 86974680
Alternative Names: JNJ-86974680Latest Information Update: 27 Nov 2023
At a glance
- Originator Johnson & Johnson Innovation
- Class Antineoplastics
- Mechanism of Action Adenosine A2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 13 Nov 2023 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Combination therapy) in USA (PO) (NCT06116786)
- 08 Nov 2023 Preclinical trials in Non-small cell lung cancer in USA (unspecified route) before November 2023 (NCT06116786)
- 03 Nov 2023 Johnson & Johnson Innovation plans a phase I trial for Non-small cell lung cancer (Combination therapy, Late-stage disease) in unspecified location (unspecified) in November 2023 (NCT06116786)